 |
|
Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine
Richard E. Chaisson, MD;
Jeanne Keruly, RN;
Douglas D. Richman, MD;
Richard D. Moore, MD, MSH
Arch Intern Med. 1992;152(10):2009-2013.
Abstract
| |
Background.—
Pneumocystis carinii pneumonia (PCP) is a major cause of morbidity and mortality in persons with advanced human immunodeficiency virus (HIV) infection. We assessed the impact of prophylaxis for PCP on survival in patients with advanced HIV disease who were treated with zidovudine.
Methods.—
A cohort of 1048 patients with prior PCP (N=437), another acquired immunodeficiency syndrome-defining diagnosis (N=168) or acquired immunodeficiency syndrome—related complex (N=443) and with less than 0.250x109/L CD4 cells initiated zidovudine treatment between April 1987 and April 1988. They were then followed up for 24 months. Morbidity and mortality outcomes were assessed every 2 months. A time-dependent, Cox proportional hazards model was used to identify factors associated with new episodes of PCP and with survival.
Results.—
Three hundred thirty-six patients (32%) developed PCP after beginning treatment with zidovudine, with a 24-month actuarial rate of 41 %. Patients with prior PCP were more likely to develop PCP during follow up (40%) than those without a history of PCP at entry (27% with PCP at follow-up). Other factors associated with developing PCP were baseline acquired immunodeficiency syndrome vs acquired immunodeficiency syndrome—related complex, and dose interruptions of zidovudine. Thirty-six (17%) of 210 patients who received trimethoprim-sulfamethoxazole prophylaxis developed PCP vs 299 (36%) of 838 who never received trimethoprim-sulfamethoxazole (odds ratio, 0.48). One hundred seven (22%) of 483 patients who ever received aerosol pentamidine prophylaxis developed PCP vs 228 (40%) of 565 who did not receive aerosol pentamidine (odds ratio, 0.55). In a time-dependent Cox proportional hazards analysis, trimethoprim-sulfamethoxazole (relative hazard, 0.21; 95% confidence interval [CI], 0.11 to 0.4) and aerosol pentamidine prophylaxis (relative hazard, 0.25; 95% CI, 0.16 to 0.39) were associated with decreased risk of PCP. Pneumocystis carinii pneumonia during follow-up was strongly associated with death when controlling for other factors (odds ratio, 1.8). For all patients, aerosol pentamidine prophylaxis was associated with a reduced risk of death during follow-up (relative hazard, 0.59; 95% CI, 0.44 to 0.78), while trimethoprim-sulfamethoxazole showed a weaker association (relative hazard, 0.74; 95% CI, 0.54 to 1.1). However, there was a significantly reduced risk of death overall for patients who consistently used trimethoprim-sulfamethoxazole (relative hazard, 0.55; 95% CI, 0.35 to 0.88) or aerosol pentamidine (relative hazard, 0.57; 95% CI, 0.42 to 0.77) and this was most pronounced in patients with a baseline history of PCP.
Discussion and Conclusions.—
Pneumocystis carinii pneumonia was common in advanced HIV infection treated with zidovudine. Prophylaxis with trimethoprim-sulfamethoxazole and aerosol pentamidine both were associated with a decreased likelihood of PCP, and consistent use of each was associated with improved survival. Prophylaxis for PCP is associated with prolonged survival for patients with advanced HIV disease.
(Arch Intern Med. 1992;152:2009-2013)
Author Affiliations
the Zidovudine Epidemiology Group
From the Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md (Drs Chaisson and Moore and Ms Keruly); and the Departments of Pathology and Medicine, Veterans Affairs Medical Center and University of California, San Diego (Dr Richman).
Footnotes
Accepted for publication April 10, 1992.
Reprint requests to the AIDS Service, The Johns Hopkins University School of Medicine, 1830 E Monument St, Suite 7400, Baltimore, MD 21205 (Dr Chaisson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
IL-10 Modulates Host Responses and Lung Damage Induced by Pneumocystis carinii Infection
Qureshi et al.
J. Immunol. 2003;170:1002-1009.
ABSTRACT
| FULL TEXT
Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection
Lawn et al.
Clin. Microbiol. Rev. 2001;14:753-777.
ABSTRACT
| FULL TEXT
Atovaquone Compared with Dapsone for the Prevention of Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both
El-Sadr et al.
NEJM 1998;339:1889-1895.
ABSTRACT
| FULL TEXT
Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival
Kitahata et al.
NEJM 1996;334:701-707.
ABSTRACT
| FULL TEXT
Trends in Infectious Diseases and Cancers among Persons Dying of HIV Infection in the United States from 1987 to 1992
Selik et al.
ANN INTERN MED 1995;123:933-936.
ABSTRACT
| FULL TEXT
Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease
Chaisson et al.
NEJM 1995;333:751-756.
ABSTRACT
| FULL TEXT
A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection
Bozzette et al.
NEJM 1995;332:693-699.
ABSTRACT
| FULL TEXT
Implications of Generalists' Slow Adoption of Zidovudine in Clinical Practice
Markson et al.
Arch Intern Med 1994;154:1497-1504.
ABSTRACT
Changes in AIDS Survival Time in Two San Francisco Cohorts of Homosexual Men, 1983 to 1993
Osmond et al.
JAMA 1994;271:1083-1087.
ABSTRACT
Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community
Moore et al.
NEJM 1994;330:763-768.
ABSTRACT
| FULL TEXT
Risk Factors for Kaposi's Sarcoma in Patients With Advanced Human Immunodeficiency Virus Disease Treated With Zidovudine
Gallant et al.
Arch Intern Med 1994;154:566-572.
ABSTRACT
|
